糖尿病肾病患者血TNF-α和PAF的检测及其临床意义

Detection and clinical significance of platelet-activated factor (PAF) and tumornecrosis factor α(TNF-α) in the patients with diabetic nephropathy

目的探讨肿瘤坏死因子α(TNF-α)和血小板活化因子(PAF)在糖尿病肾病诊治中的应用价值。方法采用生物活性法及ELISA双抗体酶联免疫吸附法,测定30例糖尿病无肾病患者和35例糖尿病肾病患者和31例正常对照组血浆PAF及血清TNF-α的水平。结果TNF-α及PAF水平,糖尿病肾病患者组[(200·18±34·38)ng/L,(2·17±0·31)μg/L]与糖尿病无肾病患者[(144·27±18·74)ng/L,(1·80±0·21)μg/L]均较正常对照组[(81·40±5·81)ng/L,(1·22±0·13)μg/L]明显增高,差异有统计学意义(P<0·01),糖尿病肾病组较糖尿病无肾病组高,差异有统计学意义(P<0·01)。结论血清TNF-α和血浆PAF在糖尿病肾病患者中显著升高,提示两者在糖尿病肾病进程中起着重要作用,其测定可能有助于糖尿病及其并发症的早期诊断和病情的监测。

Objective To study the clinical value of tumor necrosis factor α（TNF-α）and platelet-acfivated factor （PAF） in patients with diabetic nephropathy. Methods The expression of PAF and TNF-α were detected by bioactivity and enzyme linked immunosorbent assay in 30 diabetes patients without diabetic nephropathyand 35 patients with diabetic nephropathy and 31 patients of normal control group. Results TNF- α and PAF levels in diabetic patients without nephropathyand [ （ 144.27± 18.74）ng/L, （ 1.80 ± 0.21 ）μ/L] and diabetic nephropathy [ （200.18± 34.38）ng/L, （2.17 ± 0.31 ）μg/L] patients were markedly higher than that in normal control group[ （81.40 ±5.81 ） ng/L, （ 1.22 ± 0.13）μg/ L]（P 〈0.01）,TNF-α and PAF levels in patients with diabetic nephropathy were markedly higher than that in patients with non-diabetic nephropathyand（ P 〈 0.01 ）. Conclusion TNF-αand PAF in patients with diabetic may play a very important role in diabetic nephropathy. The measurement of TNF-α and PAF may contribute to the early diagnosis and monitoring of diabetes and its complication.